Analyst Ratings for [PSNL] Personalis, Inc.

PSNL Personalis, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.

2/6/23	Upgrades	Hold Buy	X
PSNL Personalis Needham
$8
1/7/22	Upgrades	Neutral Buy	X
PSNL Personalis BofA Securities
$27 $23
11/3/21	Downgrades	Buy Hold	X
PSNL Personalis Needham
10/15/21	Resumed	Outperform	X
PSNL Personalis Cowen
5/6/21	Upgrades	Perform Outperform	X
PSNL Personalis Oppenheimer
$28
1/28/21	Initiated	Buy	X
PSNL Personalis Truist
$50
1/4/21	Downgrades	Buy Neutral	X
PSNL Personalis BofA Securities
$40
7/15/19	Initiated	Neutral	X
PSNL Personalis BofA/Merrill
$27
7/15/19	Initiated	Outperform	X
PSNL Personalis Cowen
7/15/19	Initiated	Overweight	X
PSNL Personalis Morgan Stanley
$28
7/15/19	Initiated	Outperform	X
PSNL Personalis Oppenheimer
$29